Global Cardiopulmonary Autotransfusion System Supply, Demand and Key Producers, 2026-2032

November 2026 | 105 pages | ID: G54D9EF1AEFEEN
GlobalInfoResearch

US$ 4,480.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The global Cardiopulmonary Autotransfusion System market size is expected to reach $ 157 million by 2032, rising at a market growth of 5.0% CAGR during the forecast period (2026-2032).

Cardiopulmonary Autotransfusion System refers to a medical blood-management system designed to collect blood lost from a patient during or around surgery, process the recovered blood through filtration, centrifugal separation, washing and concentration, and prepare concentrated autologous red blood cells for reinfusion to the same patient. The system typically integrates or connects with blood collection reservoirs, aspiration and anticoagulation lines, centrifugal processing components, pumps, sensors, control software, reinfusion bags and waste-management components. Current product architectures primarily use discontinuous bowl-based centrifugation or continuous-flow centrifugation, with varying levels of automated processing, manual override capability, vacuum integration and support for intraoperative, postoperative or broader perioperative blood management. Cardiopulmonary Autotransfusion System is particularly relevant to procedures with expected moderate-to-high blood loss, including cardiovascular, orthopedic, vascular, trauma, transplant, thoracic, obstetric and gynecologic, neurological and general surgery, and forms an important equipment component within perioperative patient blood management programs.

Key Findings

Autotransfusion centers on washed red cell recovery and patient reinfusion

Cardiovascular surgery remains a core high blood loss application

Automation is becoming central to system workflow and process consistency

Continuous flow and bowl based platforms remain principal architectures

Disposable processing sets create a recurring consumables demand structure

Market Trends

The development of Cardiopulmonary Autotransfusion System is increasingly aligned with the broader transition from isolated transfusion equipment toward integrated patient blood management. Hospitals are placing greater emphasis on reducing unnecessary allogeneic transfusion, preserving a patient's own red blood cells and standardizing perioperative blood-management workflows. Technology development is therefore moving toward greater automation, faster processing, more stable washing performance, intelligent sensing, optimized suction control and easier switching between routine and emergency operating modes. At the same time, manufacturers are improving touchscreen interfaces, automated protocol selection, operating-data capture and connectivity to reduce dependence on manual intervention. Continuous-flow platforms provide an alternative to conventional bowl-based processing, while bowl-based systems continue to evolve through improved sensing, automated control and multiple processing-volume configurations. This means future product differentiation is likely to depend increasingly on the overall quality and consistency of blood recovery, workflow efficiency and usability rather than centrifugation capability alone. WHO's patient blood management guidance also identifies autologous cell salvage as an important blood-conservation option where clinically indicated and resources permit, reinforcing its long-term role in perioperative care.

Market Dynamics

Drivers

The principal structural driver for the Cardiopulmonary Autotransfusion System market is the continued institutionalization of patient blood management. Blood conservation has become increasingly important because hospitals must balance transfusion safety, blood-product availability and appropriate use of donor blood, particularly in operations associated with substantial blood loss. Autologous cell salvage provides a practical means of recovering and processing the patient's own shed blood and can therefore complement restrictive transfusion strategies, anemia management, hemostatic management and other perioperative blood-conservation measures. Demand is also supported by the continuing volume of cardiovascular, orthopedic, vascular, transplant and trauma procedures in which clinically meaningful blood loss may occur. In 2025 guidance, WHO explicitly included automated autologous blood collection and reinfusion devices among blood-management measures that healthcare organizations can consider where indicated, supporting the integration of these systems into more standardized hospital blood-management pathways.

Restraints

Market expansion is constrained by the fact that Cardiopulmonary Autotransfusion System is not a universal requirement for every surgical procedure. The economic value of the system depends strongly on expected blood loss, procedure volume, institutional transfusion practices and the hospital's ability to maintain trained operators and standardized protocols. Equipment acquisition is only one element of total operating cost, as each procedure also requires dedicated disposable processing sets, reservoirs, tubing, bags and other consumables. Hospitals with low volumes of high-blood-loss surgery may therefore find utilization efficiency less attractive than large tertiary centers. Clinical use also requires careful assessment when collected blood could be contaminated by surgical-field materials, infection or other undesirable substances, which limits indiscriminate application and places significant responsibility on clinical protocols and trained personnel.

Opportunities

Future opportunities are shifting from simply increasing equipment installations toward expanding the range of procedures in which autologous blood recovery can be incorporated into standardized perioperative pathways. Cardiovascular surgery remains an established application, while orthopedic reconstruction, major vascular procedures, transplant surgery, trauma, obstetric hemorrhage and other high-blood-loss operations provide additional opportunities for broader utilization. Product development can also address hospitals with different procedure volumes through more flexible processing capacities, simpler setup, automated operating programs and improved emergency-processing capability. Another opportunity lies in connecting Cardiopulmonary Autotransfusion System with broader digital blood-management workflows, allowing procedure data, processing parameters and device utilization to be documented more systematically. As patient blood management becomes more widely implemented, manufacturers able to combine equipment, disposable sets, clinical training and workflow support should be better positioned to convert device installation into sustained procedural utilization.

Challenges

The principal challenge is maintaining highly consistent blood-processing quality under variable surgical conditions. Blood-loss volume, hematocrit, anticoagulation, aspiration conditions and contamination levels may vary significantly between procedures, requiring systems to adapt while maintaining reliable separation, washing and concentration performance. Manufacturers must also balance greater automation with sufficient manual control for experienced perfusionists and other clinical operators. Regulatory and quality requirements create an additional barrier because autotransfusion equipment and its patient-contacting disposable components require rigorous verification, manufacturing control and post-market management. In the United States, autotransfusion apparatus is regulated as a Class II medical device under 21 CFR 868.5830, illustrating the level of regulatory oversight required for this product category. Hospitals must simultaneously maintain operator competency, procedural protocols and quality-control practices, so successful commercialization depends on clinical implementation capabilities as well as equipment performance.

Industry Chain Analysis

The Cardiopulmonary Autotransfusion System industry chain combines durable medical equipment manufacturing with a significant single-use consumables component. Upstream inputs include centrifuge and pump assemblies, motors, pressure and optical sensors, electronic control components, displays, software, medical-grade polymers, filters, tubing, connectors, reservoirs, centrifuge bowls or continuous-processing chambers, blood bags and anticoagulation-related fluid-path components. These materials and components must meet stringent requirements for blood compatibility, dimensional consistency, sterility and manufacturing reliability. Midstream manufacturers integrate mechanical, fluid-control, sensing and software technologies into reusable consoles while designing matched disposable blood-processing circuits. Product development therefore requires simultaneous optimization of device engineering and disposable-set performance rather than treating them as separate products.

Downstream customers are primarily hospitals and surgical centers with operating rooms capable of managing procedures involving meaningful blood loss, particularly cardiac surgery centers and large tertiary hospitals. Perfusion teams, anesthesiology departments, operating-room personnel and patient blood management programs are key users or decision participants. Commercial value is created through a combined installed-base and procedure-volume model: the reusable console establishes the clinical platform, while each operation generates demand for processing sets, reservoirs, aspiration and anticoagulation lines, blood bags and related disposables. As a result, equipment reliability, consumable compatibility, training and service capability directly affect both customer retention and long-term utilization. Haemonetics and Medtronic product configurations illustrate this equipment-plus-disposables structure clearly.

Segment Insights

From a technology perspective, Cardiopulmonary Autotransfusion System is centered on two principal processing architectures: discontinuous bowl-based centrifugation and continuous-flow centrifugation. Bowl-based systems have developed around different bowl capacities, automated filling, washing and emptying cycles, while continuous-flow systems integrate multiple processing stages into a continuously operating disposable circuit. The commercial choice between these approaches is influenced by processing speed, minimum blood volume requirements, wash performance, procedural familiarity, consumable configuration and workflow preferences rather than by a single technical parameter. Fresenius Kabi's CATSmart demonstrates the continuous-flow approach, while systems from other confirmed suppliers demonstrate continued technological development of bowl-based processing.

Automation represents another important segmentation dimension. Fully automated systems increasingly integrate sensing, automatic filling and washing control, pump adjustment and preset clinical protocols, while automatic systems with manual override preserve operator flexibility in unusual blood-loss conditions. Products can also be differentiated by procedural coverage, ranging from intraoperative recovery to combinations of intraoperative and postoperative processing and, in selected systems, preoperative blood-component sequestration. Vacuum architecture provides a further distinction between integrated suction systems and external or modular vacuum configurations. These dimensions indicate that future competition will increasingly center on the ability to adapt a common platform to multiple clinical workflows without increasing operational complexity.

Downstream Market Opportunities

Cardiovascular surgery is a core application for Cardiopulmonary Autotransfusion System because cardiothoracic procedures can involve substantial blood exposure and have long-established perfusion and blood-management workflows. Beyond cardiac surgery, major orthopedic procedures, vascular surgery, trauma, transplantation and selected obstetric, neurological, thoracic and general surgical procedures create additional opportunities when anticipated blood loss justifies cell salvage. The most attractive downstream opportunity is therefore not simply expansion into more surgical specialties, but deeper integration of autotransfusion into standardized protocols for procedures with predictable blood-loss risk. Hospitals that coordinate surgeons, anesthesiologists, perfusionists and transfusion services through structured patient blood management programs can achieve higher system utilization than facilities where cell salvage remains an ad-hoc response to individual procedures.

Regional Insights

Regional development of the Cardiopulmonary Autotransfusion System market is influenced more by surgical infrastructure, patient blood management maturity and hospital purchasing capacity than by a single geographic factor. In developed healthcare markets, replacement demand increasingly centers on automated workflow, blood-processing consistency, operator efficiency, data management and integration with existing perioperative practices. Hospitals with established cardiac surgery, transplantation, complex orthopedics and trauma programs provide the strongest environment for recurring utilization because system economics improve when reusable equipment is supported by sufficient procedural throughput.

In emerging healthcare markets, the opportunity is more closely associated with expansion of tertiary hospitals, cardiovascular and orthopedic surgical capacity, improved blood-management awareness and localization of equipment and consumable supply. However, capital budgets, operator training, disposable-set availability and uneven implementation of patient blood management can slow adoption. This creates differentiated regional strategies: mature markets favor technology replacement and workflow upgrades, while developing markets offer greater potential for installed-base expansion and localized clinical education. WHO's recent patient blood management guidance specifically addresses implementation across healthcare systems with differing resource levels, supporting the long-term expansion of cell-salvage practices beyond the most established markets.

Report Scope

This report studies the global Cardiopulmonary Autotransfusion System production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Cardiopulmonary Autotransfusion System and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Cardiopulmonary Autotransfusion System that contribute to its increasing demand across many markets.

Highlights and key features of the study

  • Global Cardiopulmonary Autotransfusion System total production and demand, 2021-2032, (K Units)
  • Global Cardiopulmonary Autotransfusion System total production value, 2021-2032, (USD Million)
  • Global Cardiopulmonary Autotransfusion System production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
  • Global Cardiopulmonary Autotransfusion System consumption by region & country, CAGR, 2021-2032 & (K Units)
  • U.S. VS China: Cardiopulmonary Autotransfusion System domestic production, consumption, key domestic manufacturers and share
  • Global Cardiopulmonary Autotransfusion System production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
  • Global Cardiopulmonary Autotransfusion System production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
  • Global Cardiopulmonary Autotransfusion System production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global Cardiopulmonary Autotransfusion System market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include LivaNova, Haemonetics, Medtronic, Fresenius Kabi, Lifemotion, Rocket Medical, Terumo, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Cardiopulmonary Autotransfusion System market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (USD/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Cardiopulmonary Autotransfusion System Market, By Region:

  • United States
  • China
  • Europe
  • Japan
  • South Korea
  • ASEAN
  • India
  • Rest of World

Market Segmentation

Global Cardiopulmonary Autotransfusion System Market, Segmentation by Type:

  • Unwashed ATS
  • Washed ATS

Global Cardiopulmonary Autotransfusion System Market, Segmentation by Level of Automation:

  • Integrated Vacuum Autotransfusion System
  • External or Modular Vacuum Autotransfusion System

Global Cardiopulmonary Autotransfusion System Market, Segmentation by Blood Centrifugation Method:

  • Discontinuous Bowl-Based Autotransfusion System
  • Continuous-Flow Autotransfusion System

Global Cardiopulmonary Autotransfusion System Market, Segmentation by Application:

  • Heart Surgery
  • Great Organ Transplant Surgery
  • Other Surgery

Companies Profiled:

  • LivaNova
  • Haemonetics
  • Medtronic
  • Fresenius Kabi
  • Lifemotion
  • Rocket Medical
  • Terumo

Key Questions Answered

1. How big is the global Cardiopulmonary Autotransfusion System market?
2. What is the demand of the global Cardiopulmonary Autotransfusion System market?
3. What is the year over year growth of the global Cardiopulmonary Autotransfusion System market?
4. What is the total value of the global Cardiopulmonary Autotransfusion System market?
5. Who are the Major Players in the global Cardiopulmonary Autotransfusion System market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY

1.1 Cardiopulmonary Autotransfusion System Introduction
1.2 World Cardiopulmonary Autotransfusion System Supply & Forecast
  1.2.1 World Cardiopulmonary Autotransfusion System Production Value (2021 & 2025 & 2032)
  1.2.2 World Cardiopulmonary Autotransfusion System Production (2021-2032)
  1.2.3 World Cardiopulmonary Autotransfusion System Pricing Trends (2021-2032)
1.3 World Cardiopulmonary Autotransfusion System Production by Region (Based on Production Site)
  1.3.1 World Cardiopulmonary Autotransfusion System Production Value by Region (2021-2032)
  1.3.2 World Cardiopulmonary Autotransfusion System Production by Region (2021-2032)
  1.3.3 World Cardiopulmonary Autotransfusion System Average Price by Region (2021-2032)
  1.3.4 North America Cardiopulmonary Autotransfusion System Production (2021-2032)
  1.3.5 Europe Cardiopulmonary Autotransfusion System Production (2021-2032)
  1.3.6 China Cardiopulmonary Autotransfusion System Production (2021-2032)
  1.3.7 Japan Cardiopulmonary Autotransfusion System Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
  1.4.1 Cardiopulmonary Autotransfusion System Market Drivers
  1.4.2 Factors Affecting Demand
  1.4.3 Cardiopulmonary Autotransfusion System Major Market Trends

2 DEMAND SUMMARY

2.1 World Cardiopulmonary Autotransfusion System Demand (2021-2032)
2.2 World Cardiopulmonary Autotransfusion System Consumption by Region
  2.2.1 World Cardiopulmonary Autotransfusion System Consumption by Region (2021-2026)
  2.2.2 World Cardiopulmonary Autotransfusion System Consumption Forecast by Region (2027-2032)
2.3 United States Cardiopulmonary Autotransfusion System Consumption (2021-2032)
2.4 China Cardiopulmonary Autotransfusion System Consumption (2021-2032)
2.5 Europe Cardiopulmonary Autotransfusion System Consumption (2021-2032)
2.6 Japan Cardiopulmonary Autotransfusion System Consumption (2021-2032)
2.7 South Korea Cardiopulmonary Autotransfusion System Consumption (2021-2032)
2.8 ASEAN Cardiopulmonary Autotransfusion System Consumption (2021-2032)
2.9 India Cardiopulmonary Autotransfusion System Consumption (2021-2032)

3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS

3.1 World Cardiopulmonary Autotransfusion System Production Value by Manufacturer (2021-2026)
3.2 World Cardiopulmonary Autotransfusion System Production by Manufacturer (2021-2026)
3.3 World Cardiopulmonary Autotransfusion System Average Price by Manufacturer (2021-2026)
3.4 Cardiopulmonary Autotransfusion System Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
  3.5.1 Global Cardiopulmonary Autotransfusion System Industry Rank of Major Manufacturers
  3.5.2 Global Concentration Ratios (CR4) for Cardiopulmonary Autotransfusion System in 2025
  3.5.3 Global Concentration Ratios (CR8) for Cardiopulmonary Autotransfusion System in 2025
3.6 Cardiopulmonary Autotransfusion System Market: Overall Company Footprint Analysis
  3.6.1 Cardiopulmonary Autotransfusion System Market: Region Footprint
  3.6.2 Cardiopulmonary Autotransfusion System Market: Company Product Type Footprint
  3.6.3 Cardiopulmonary Autotransfusion System Market: Company Product Application Footprint
3.7 Competitive Environment
  3.7.1 Historical Structure of the Industry
  3.7.2 Barriers of Market Entry
  3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations

4 UNITED STATES VS CHINA VS REST OF THE WORLD

4.1 United States VS China: Cardiopulmonary Autotransfusion System Production Value Comparison
  4.1.1 United States VS China: Cardiopulmonary Autotransfusion System Production Value Comparison (2021 & 2025 & 2032)
  4.1.2 United States VS China: Cardiopulmonary Autotransfusion System Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Cardiopulmonary Autotransfusion System Production Comparison
  4.2.1 United States VS China: Cardiopulmonary Autotransfusion System Production Comparison (2021 & 2025 & 2032)
  4.2.2 United States VS China: Cardiopulmonary Autotransfusion System Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Cardiopulmonary Autotransfusion System Consumption Comparison
  4.3.1 United States VS China: Cardiopulmonary Autotransfusion System Consumption Comparison (2021 & 2025 & 2032)
  4.3.2 United States VS China: Cardiopulmonary Autotransfusion System Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Cardiopulmonary Autotransfusion System Manufacturers and Market Share, 2021-2026
  4.4.1 United States Based Cardiopulmonary Autotransfusion System Manufacturers, Headquarters and Production Site (States, Country)
  4.4.2 United States Based Manufacturers Cardiopulmonary Autotransfusion System Production Value (2021-2026)
  4.4.3 United States Based Manufacturers Cardiopulmonary Autotransfusion System Production (2021-2026)
4.5 China Based Cardiopulmonary Autotransfusion System Manufacturers and Market Share
  4.5.1 China Based Cardiopulmonary Autotransfusion System Manufacturers, Headquarters and Production Site (Province, Country)
  4.5.2 China Based Manufacturers Cardiopulmonary Autotransfusion System Production Value (2021-2026)
  4.5.3 China Based Manufacturers Cardiopulmonary Autotransfusion System Production (2021-2026)
4.6 Rest of World Based Cardiopulmonary Autotransfusion System Manufacturers and Market Share, 2021-2026
  4.6.1 Rest of World Based Cardiopulmonary Autotransfusion System Manufacturers, Headquarters and Production Site (State, Country)
  4.6.2 Rest of World Based Manufacturers Cardiopulmonary Autotransfusion System Production Value (2021-2026)
  4.6.3 Rest of World Based Manufacturers Cardiopulmonary Autotransfusion System Production (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World Cardiopulmonary Autotransfusion System Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
  5.2.1 Unwashed ATS
  5.2.2 Washed ATS
5.3 Market Segment by Type
  5.3.1 World Cardiopulmonary Autotransfusion System Production by Type (2021-2032)
  5.3.2 World Cardiopulmonary Autotransfusion System Production Value by Type (2021-2032)
  5.3.3 World Cardiopulmonary Autotransfusion System Average Price by Type (2021-2032)

6 MARKET ANALYSIS BY LEVEL OF AUTOMATION

6.1 World Cardiopulmonary Autotransfusion System Market Size Overview by Level of Automation: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Level of Automation
  6.2.1 Integrated Vacuum Autotransfusion System
  6.2.2 External or Modular Vacuum Autotransfusion System
6.3 Market Segment by Level of Automation
  6.3.1 World Cardiopulmonary Autotransfusion System Production by Level of Automation (2021-2032)
  6.3.2 World Cardiopulmonary Autotransfusion System Production Value by Level of Automation (2021-2032)
  6.3.3 World Cardiopulmonary Autotransfusion System Average Price by Level of Automation (2021-2032)

7 MARKET ANALYSIS BY BLOOD CENTRIFUGATION METHOD

7.1 World Cardiopulmonary Autotransfusion System Market Size Overview by Blood Centrifugation Method: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Blood Centrifugation Method
  7.2.1 Discontinuous Bowl-Based Autotransfusion System
  7.2.2 Continuous-Flow Autotransfusion System
7.3 Market Segment by Blood Centrifugation Method
  7.3.1 World Cardiopulmonary Autotransfusion System Production by Blood Centrifugation Method (2021-2032)
  7.3.2 World Cardiopulmonary Autotransfusion System Production Value by Blood Centrifugation Method (2021-2032)
  7.3.3 World Cardiopulmonary Autotransfusion System Average Price by Blood Centrifugation Method (2021-2032)

8 MARKET ANALYSIS BY APPLICATION

8.1 World Cardiopulmonary Autotransfusion System Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
  8.2.1 Heart Surgery
  8.2.2 Great Organ Transplant Surgery
  8.2.3 Other Surgery
8.3 Market Segment by Application
  8.3.1 World Cardiopulmonary Autotransfusion System Production by Application (2021-2032)
  8.3.2 World Cardiopulmonary Autotransfusion System Production Value by Application (2021-2032)
  8.3.3 World Cardiopulmonary Autotransfusion System Average Price by Application (2021-2032)

9 COMPANY PROFILES

9.1 LivaNova
  9.1.1 LivaNova Details
  9.1.2 LivaNova Major Business
  9.1.3 LivaNova Cardiopulmonary Autotransfusion System Product and Services
  9.1.4 LivaNova Cardiopulmonary Autotransfusion System Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.1.5 LivaNova Recent Developments/Updates
  9.1.6 LivaNova Competitive Strengths & Weaknesses
9.2 Haemonetics
  9.2.1 Haemonetics Details
  9.2.2 Haemonetics Major Business
  9.2.3 Haemonetics Cardiopulmonary Autotransfusion System Product and Services
  9.2.4 Haemonetics Cardiopulmonary Autotransfusion System Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.2.5 Haemonetics Recent Developments/Updates
  9.2.6 Haemonetics Competitive Strengths & Weaknesses
9.3 Medtronic
  9.3.1 Medtronic Details
  9.3.2 Medtronic Major Business
  9.3.3 Medtronic Cardiopulmonary Autotransfusion System Product and Services
  9.3.4 Medtronic Cardiopulmonary Autotransfusion System Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.3.5 Medtronic Recent Developments/Updates
  9.3.6 Medtronic Competitive Strengths & Weaknesses
9.4 Fresenius Kabi
  9.4.1 Fresenius Kabi Details
  9.4.2 Fresenius Kabi Major Business
  9.4.3 Fresenius Kabi Cardiopulmonary Autotransfusion System Product and Services
  9.4.4 Fresenius Kabi Cardiopulmonary Autotransfusion System Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.4.5 Fresenius Kabi Recent Developments/Updates
  9.4.6 Fresenius Kabi Competitive Strengths & Weaknesses
9.5 Lifemotion
  9.5.1 Lifemotion Details
  9.5.2 Lifemotion Major Business
  9.5.3 Lifemotion Cardiopulmonary Autotransfusion System Product and Services
  9.5.4 Lifemotion Cardiopulmonary Autotransfusion System Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.5.5 Lifemotion Recent Developments/Updates
  9.5.6 Lifemotion Competitive Strengths & Weaknesses
9.6 Rocket Medical
  9.6.1 Rocket Medical Details
  9.6.2 Rocket Medical Major Business
  9.6.3 Rocket Medical Cardiopulmonary Autotransfusion System Product and Services
  9.6.4 Rocket Medical Cardiopulmonary Autotransfusion System Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.6.5 Rocket Medical Recent Developments/Updates
  9.6.6 Rocket Medical Competitive Strengths & Weaknesses
9.7 Terumo
  9.7.1 Terumo Details
  9.7.2 Terumo Major Business
  9.7.3 Terumo Cardiopulmonary Autotransfusion System Product and Services
  9.7.4 Terumo Cardiopulmonary Autotransfusion System Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.7.5 Terumo Recent Developments/Updates
  9.7.6 Terumo Competitive Strengths & Weaknesses

10 INDUSTRY CHAIN ANALYSIS

10.1 Cardiopulmonary Autotransfusion System Industry Chain
10.2 Cardiopulmonary Autotransfusion System Upstream Analysis
  10.2.1 Cardiopulmonary Autotransfusion System Core Raw Materials
  10.2.2 Main Manufacturers of Cardiopulmonary Autotransfusion System Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Cardiopulmonary Autotransfusion System Production Mode
10.6 Cardiopulmonary Autotransfusion System Procurement Model
10.7 Cardiopulmonary Autotransfusion System Industry Sales Model and Sales Channels
  10.7.1 Cardiopulmonary Autotransfusion System Sales Model
  10.7.2 Cardiopulmonary Autotransfusion System Typical Distributors

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES

Table 1. World Cardiopulmonary Autotransfusion System Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Cardiopulmonary Autotransfusion System Production Value by Region (2021-2026) & (USD Million)
Table 3. World Cardiopulmonary Autotransfusion System Production Value by Region (2027-2032) & (USD Million)
Table 4. World Cardiopulmonary Autotransfusion System Production Value Market Share by Region (2021-2026)
Table 5. World Cardiopulmonary Autotransfusion System Production Value Market Share by Region (2027-2032)
Table 6. World Cardiopulmonary Autotransfusion System Production by Region (2021-2026) & (K Units)
Table 7. World Cardiopulmonary Autotransfusion System Production by Region (2027-2032) & (K Units)
Table 8. World Cardiopulmonary Autotransfusion System Production Market Share by Region (2021-2026)
Table 9. World Cardiopulmonary Autotransfusion System Production Market Share by Region (2027-2032)
Table 10. World Cardiopulmonary Autotransfusion System Average Price by Region (2021-2026) & (USD/Unit)
Table 11. World Cardiopulmonary Autotransfusion System Average Price by Region (2027-2032) & (USD/Unit)
Table 12. Cardiopulmonary Autotransfusion System Major Market Trends
Table 13. World Cardiopulmonary Autotransfusion System Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Units)
Table 14. World Cardiopulmonary Autotransfusion System Consumption by Region (2021-2026) & (K Units)
Table 15. World Cardiopulmonary Autotransfusion System Consumption Forecast by Region (2027-2032) & (K Units)
Table 16. World Cardiopulmonary Autotransfusion System Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Cardiopulmonary Autotransfusion System Producers in 2025
Table 18. World Cardiopulmonary Autotransfusion System Production by Manufacturer (2021-2026) & (K Units)
Table 19. Production Market Share of Key Cardiopulmonary Autotransfusion System Producers in 2025
Table 20. World Cardiopulmonary Autotransfusion System Average Price by Manufacturer (2021-2026) & (USD/Unit)
Table 21. Global Cardiopulmonary Autotransfusion System Company Evaluation Quadrant
Table 22. World Cardiopulmonary Autotransfusion System Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Cardiopulmonary Autotransfusion System Production Site of Key Manufacturer
Table 24. Cardiopulmonary Autotransfusion System Market: Company Product Type Footprint
Table 25. Cardiopulmonary Autotransfusion System Market: Company Product Application Footprint
Table 26. Cardiopulmonary Autotransfusion System Competitive Factors
Table 27. Cardiopulmonary Autotransfusion System New Entrant and Capacity Expansion Plans
Table 28. Cardiopulmonary Autotransfusion System Mergers & Acquisitions Activity
Table 29. United States VS China Cardiopulmonary Autotransfusion System Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Cardiopulmonary Autotransfusion System Production Comparison, (2021 & 2025 & 2032) & (K Units)
Table 31. United States VS China Cardiopulmonary Autotransfusion System Consumption Comparison, (2021 & 2025 & 2032) & (K Units)
Table 32. United States Based Cardiopulmonary Autotransfusion System Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Cardiopulmonary Autotransfusion System Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Cardiopulmonary Autotransfusion System Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Cardiopulmonary Autotransfusion System Production (2021-2026) & (K Units)
Table 36. United States Based Manufacturers Cardiopulmonary Autotransfusion System Production Market Share (2021-2026)
Table 37. China Based Cardiopulmonary Autotransfusion System Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Cardiopulmonary Autotransfusion System Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Cardiopulmonary Autotransfusion System Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Cardiopulmonary Autotransfusion System Production, (2021-2026) & (K Units)
Table 41. China Based Manufacturers Cardiopulmonary Autotransfusion System Production Market Share (2021-2026)
Table 42. Rest of World Based Cardiopulmonary Autotransfusion System Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Cardiopulmonary Autotransfusion System Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Cardiopulmonary Autotransfusion System Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Cardiopulmonary Autotransfusion System Production, (2021-2026) & (K Units)
Table 46. Rest of World Based Manufacturers Cardiopulmonary Autotransfusion System Production Market Share (2021-2026)
Table 47. World Cardiopulmonary Autotransfusion System Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Cardiopulmonary Autotransfusion System Production by Type (2021-2026) & (K Units)
Table 49. World Cardiopulmonary Autotransfusion System Production by Type (2027-2032) & (K Units)
Table 50. World Cardiopulmonary Autotransfusion System Production Value by Type (2021-2026) & (USD Million)
Table 51. World Cardiopulmonary Autotransfusion System Production Value by Type (2027-2032) & (USD Million)
Table 52. World Cardiopulmonary Autotransfusion System Average Price by Type (2021-2026) & (USD/Unit)
Table 53. World Cardiopulmonary Autotransfusion System Average Price by Type (2027-2032) & (USD/Unit)
Table 54. World Cardiopulmonary Autotransfusion System Production Value by Level of Automation, (USD Million), 2021 & 2025 & 2032
Table 55. World Cardiopulmonary Autotransfusion System Production by Level of Automation (2021-2026) & (K Units)
Table 56. World Cardiopulmonary Autotransfusion System Production by Level of Automation (2027-2032) & (K Units)
Table 57. World Cardiopulmonary Autotransfusion System Production Value by Level of Automation (2021-2026) & (USD Million)
Table 58. World Cardiopulmonary Autotransfusion System Production Value by Level of Automation (2027-2032) & (USD Million)
Table 59. World Cardiopulmonary Autotransfusion System Average Price by Level of Automation (2021-2026) & (USD/Unit)
Table 60. World Cardiopulmonary Autotransfusion System Average Price by Level of Automation (2027-2032) & (USD/Unit)
Table 61. World Cardiopulmonary Autotransfusion System Production Value by Blood Centrifugation Method, (USD Million), 2021 & 2025 & 2032
Table 62. World Cardiopulmonary Autotransfusion System Production by Blood Centrifugation Method (2021-2026) & (K Units)
Table 63. World Cardiopulmonary Autotransfusion System Production by Blood Centrifugation Method (2027-2032) & (K Units)
Table 64. World Cardiopulmonary Autotransfusion System Production Value by Blood Centrifugation Method (2021-2026) & (USD Million)
Table 65. World Cardiopulmonary Autotransfusion System Production Value by Blood Centrifugation Method (2027-2032) & (USD Million)
Table 66. World Cardiopulmonary Autotransfusion System Average Price by Blood Centrifugation Method (2021-2026) & (USD/Unit)
Table 67. World Cardiopulmonary Autotransfusion System Average Price by Blood Centrifugation Method (2027-2032) & (USD/Unit)
Table 68. World Cardiopulmonary Autotransfusion System Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Cardiopulmonary Autotransfusion System Production by Application (2021-2026) & (K Units)
Table 70. World Cardiopulmonary Autotransfusion System Production by Application (2027-2032) & (K Units)
Table 71. World Cardiopulmonary Autotransfusion System Production Value by Application (2021-2026) & (USD Million)
Table 72. World Cardiopulmonary Autotransfusion System Production Value by Application (2027-2032) & (USD Million)
Table 73. World Cardiopulmonary Autotransfusion System Average Price by Application (2021-2026) & (USD/Unit)
Table 74. World Cardiopulmonary Autotransfusion System Average Price by Application (2027-2032) & (USD/Unit)
Table 75. LivaNova Basic Information, Manufacturing Base and Competitors
Table 76. LivaNova Major Business
Table 77. LivaNova Cardiopulmonary Autotransfusion System Product and Services
Table 78. LivaNova Cardiopulmonary Autotransfusion System Production (K Units), Price (USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. LivaNova Recent Developments/Updates
Table 80. LivaNova Competitive Strengths & Weaknesses
Table 81. Haemonetics Basic Information, Manufacturing Base and Competitors
Table 82. Haemonetics Major Business
Table 83. Haemonetics Cardiopulmonary Autotransfusion System Product and Services
Table 84. Haemonetics Cardiopulmonary Autotransfusion System Production (K Units), Price (USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Haemonetics Recent Developments/Updates
Table 86. Haemonetics Competitive Strengths & Weaknesses
Table 87. Medtronic Basic Information, Manufacturing Base and Competitors
Table 88. Medtronic Major Business
Table 89. Medtronic Cardiopulmonary Autotransfusion System Product and Services
Table 90. Medtronic Cardiopulmonary Autotransfusion System Production (K Units), Price (USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Medtronic Recent Developments/Updates
Table 92. Medtronic Competitive Strengths & Weaknesses
Table 93. Fresenius Kabi Basic Information, Manufacturing Base and Competitors
Table 94. Fresenius Kabi Major Business
Table 95. Fresenius Kabi Cardiopulmonary Autotransfusion System Product and Services
Table 96. Fresenius Kabi Cardiopulmonary Autotransfusion System Production (K Units), Price (USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Fresenius Kabi Recent Developments/Updates
Table 98. Fresenius Kabi Competitive Strengths & Weaknesses
Table 99. Lifemotion Basic Information, Manufacturing Base and Competitors
Table 100. Lifemotion Major Business
Table 101. Lifemotion Cardiopulmonary Autotransfusion System Product and Services
Table 102. Lifemotion Cardiopulmonary Autotransfusion System Production (K Units), Price (USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Lifemotion Recent Developments/Updates
Table 104. Lifemotion Competitive Strengths & Weaknesses
Table 105. Rocket Medical Basic Information, Manufacturing Base and Competitors
Table 106. Rocket Medical Major Business
Table 107. Rocket Medical Cardiopulmonary Autotransfusion System Product and Services
Table 108. Rocket Medical Cardiopulmonary Autotransfusion System Production (K Units), Price (USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. Rocket Medical Recent Developments/Updates
Table 110. Rocket Medical Competitive Strengths & Weaknesses
Table 111. Terumo Basic Information, Manufacturing Base and Competitors
Table 112. Terumo Major Business
Table 113. Terumo Cardiopulmonary Autotransfusion System Product and Services
Table 114. Terumo Cardiopulmonary Autotransfusion System Production (K Units), Price (USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Terumo Recent Developments/Updates
Table 116. Terumo Competitive Strengths & Weaknesses
Table 117. Global Key Players of Cardiopulmonary Autotransfusion System Upstream (Raw Materials)
Table 118. Global Cardiopulmonary Autotransfusion System Typical Customers
Table 119. Cardiopulmonary Autotransfusion System Typical Distributors

LIST OF FIGURES

Figure 1. Cardiopulmonary Autotransfusion System Picture
Figure 2. World Cardiopulmonary Autotransfusion System Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Cardiopulmonary Autotransfusion System Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Cardiopulmonary Autotransfusion System Production (2021-2032) & (K Units)
Figure 5. World Cardiopulmonary Autotransfusion System Average Price (2021-2032) & (USD/Unit)
Figure 6. World Cardiopulmonary Autotransfusion System Production Value Market Share by Region (2021-2032)
Figure 7. World Cardiopulmonary Autotransfusion System Production Market Share by Region (2021-2032)
Figure 8. North America Cardiopulmonary Autotransfusion System Production (2021-2032) & (K Units)
Figure 9. Europe Cardiopulmonary Autotransfusion System Production (2021-2032) & (K Units)
Figure 10. China Cardiopulmonary Autotransfusion System Production (2021-2032) & (K Units)
Figure 11. Japan Cardiopulmonary Autotransfusion System Production (2021-2032) & (K Units)
Figure 12. Cardiopulmonary Autotransfusion System Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Cardiopulmonary Autotransfusion System Consumption (2021-2032) & (K Units)
Figure 15. World Cardiopulmonary Autotransfusion System Consumption Market Share by Region (2021-2032)
Figure 16. United States Cardiopulmonary Autotransfusion System Consumption (2021-2032) & (K Units)
Figure 17. China Cardiopulmonary Autotransfusion System Consumption (2021-2032) & (K Units)
Figure 18. Europe Cardiopulmonary Autotransfusion System Consumption (2021-2032) & (K Units)
Figure 19. Japan Cardiopulmonary Autotransfusion System Consumption (2021-2032) & (K Units)
Figure 20. South Korea Cardiopulmonary Autotransfusion System Consumption (2021-2032) & (K Units)
Figure 21. ASEAN Cardiopulmonary Autotransfusion System Consumption (2021-2032) & (K Units)
Figure 22. India Cardiopulmonary Autotransfusion System Consumption (2021-2032) & (K Units)
Figure 23. Producer Shipments of Cardiopulmonary Autotransfusion System by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 24. Global Four-firm Concentration Ratios (CR4) for Cardiopulmonary Autotransfusion System Markets in 2025
Figure 25. Global Four-firm Concentration Ratios (CR8) for Cardiopulmonary Autotransfusion System Markets in 2025
Figure 26. United States VS China: Cardiopulmonary Autotransfusion System Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: Cardiopulmonary Autotransfusion System Production Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Cardiopulmonary Autotransfusion System Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States Based Manufacturers Cardiopulmonary Autotransfusion System Production Market Share 2025
Figure 30. China Based Manufacturers Cardiopulmonary Autotransfusion System Production Market Share 2025
Figure 31. Rest of World Based Manufacturers Cardiopulmonary Autotransfusion System Production Market Share 2025
Figure 32. World Cardiopulmonary Autotransfusion System Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 33. World Cardiopulmonary Autotransfusion System Production Value Market Share by Type in 2025
Figure 34. Unwashed ATS
Figure 35. Washed ATS
Figure 36. World Cardiopulmonary Autotransfusion System Production Market Share by Type (2021-2032)
Figure 37. World Cardiopulmonary Autotransfusion System Production Value Market Share by Type (2021-2032)
Figure 38. World Cardiopulmonary Autotransfusion System Average Price by Type (2021-2032) & (USD/Unit)
Figure 39. World Cardiopulmonary Autotransfusion System Production Value by Level of Automation, (USD Million), 2021 & 2025 & 2032
Figure 40. World Cardiopulmonary Autotransfusion System Production Value Market Share by Level of Automation in 2025
Figure 41. Integrated Vacuum Autotransfusion System
Figure 42. External or Modular Vacuum Autotransfusion System
Figure 43. World Cardiopulmonary Autotransfusion System Production Market Share by Level of Automation (2021-2032)
Figure 44. World Cardiopulmonary Autotransfusion System Production Value Market Share by Level of Automation (2021-2032)
Figure 45. World Cardiopulmonary Autotransfusion System Average Price by Level of Automation (2021-2032) & (USD/Unit)
Figure 46. World Cardiopulmonary Autotransfusion System Production Value by Blood Centrifugation Method, (USD Million), 2021 & 2025 & 2032
Figure 47. World Cardiopulmonary Autotransfusion System Production Value Market Share by Blood Centrifugation Method in 2025
Figure 48. Discontinuous Bowl-Based Autotransfusion System
Figure 49. Continuous-Flow Autotransfusion System
Figure 50. World Cardiopulmonary Autotransfusion System Production Market Share by Blood Centrifugation Method (2021-2032)
Figure 51. World Cardiopulmonary Autotransfusion System Production Value Market Share by Blood Centrifugation Method (2021-2032)
Figure 52. World Cardiopulmonary Autotransfusion System Average Price by Blood Centrifugation Method (2021-2032) & (USD/Unit)
Figure 53. World Cardiopulmonary Autotransfusion System Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 54. World Cardiopulmonary Autotransfusion System Production Value Market Share by Application in 2025
Figure 55. Heart Surgery
Figure 56. Great Organ Transplant Surgery
Figure 57. Other Surgery
Figure 58. World Cardiopulmonary Autotransfusion System Production Market Share by Application (2021-2032)
Figure 59. World Cardiopulmonary Autotransfusion System Production Value Market Share by Application (2021-2032)
Figure 60. World Cardiopulmonary Autotransfusion System Average Price by Application (2021-2032) & (USD/Unit)
Figure 61. Cardiopulmonary Autotransfusion System Industry Chain
Figure 62. Cardiopulmonary Autotransfusion System Procurement Model
Figure 63. Cardiopulmonary Autotransfusion System Sales Model
Figure 64. Cardiopulmonary Autotransfusion System Sales Channels, Direct Sales, and Distribution
Figure 65. Methodology
Figure 66. Research Process and Data Source